Alzheimers Disease Patient Registry

摘要 梅奥老年诊所研究(MCSA)一直是一项基于人群的认知研究 以及自2004年以来的老龄化。在这段时间内，我们评估了 认知正常的人，有轻度认知障碍(MCI)和痴呆症。我们有 评估了MCI的流行病学特征，并在近年来评估了许多MCI的生物标志物 衰老和阿尔茨海默病(AD)包括MRI、FDG PET、淀粉样PET和tau PET。在 目前的申请，我们将评估最近发表的国家老龄-阿尔茨海默氏症研究所 协会AD研究框架使用我们的人口为基础的队列。在目标1中，我们将预测和 应用该框架的临床症状评估认知功能衰退危险因素的作用 认知正常、轻度认知障碍和痴呆症参与者的分类。在目标2中，我们将预测 根据新提出的数字分级方案，框架中的认知能力下降 淀粉样蛋白阳性患者的随机对照试验。此外，由于我们正在评估一个 作为整个社会的代表性样本，我们亦会在 淀粉样蛋白阴性的人以及整个人群中也是如此。因为人们认识到 脑血管疾病在老龄化中起着重要作用，在目标3中，我们将评估 衰老与认知的脑血管疾病及其与AD病理的相互作用我们会 还利用先进的方法开发新的磁共振脑血管疾病测量方法。生物标志物 AD的措施通常是昂贵的和/或侵入性的，因此对于公众来说是不切实际的 因此，在目标4中，我们将确定和比较血浆的效用 β-淀粉样蛋白、p-tau181、总tau和神经细丝光(NFL)作为认知功能的非侵入性生物标志物 拒绝并评估与淀粉样蛋白、tau、神经退行性变和 血管疾病。最后，由于共享MCSA的丰富资源是重要的，在目标5中，我们 概述我们提议的数据共享机制，包括审查提案、标准化数据 共享协议和共享数据的物流。我们希望，继续进行 MCSA将为老龄化和AD领域提供有价值的信息。

ABSTRACT The Mayo Clinic Study of Aging (MCSA) has been functioning as a population-based study of cognition and aging since 2004. Over that timeframe, we have evaluated longitudinal cognitive trajectories of individuals who are cognitively normal, have mild cognitive impairment (MCI) and dementia. We have evaluated epidemiologic features of MCI and in recent years have evaluated many of the biomarkers of aging and Alzheimer's disease (AD) including MRI, FDG PET, amyloid PET and tau PET. In the current application, we will evaluate the recently published National Institute on Aging-Alzheimer's Association AD Research Framework using our population-based cohort. In Aim 1, we will predict and assess the role of risk factors of cognitive decline using the Framework's syndromic clinical classification of cognitively unimpaired, MCI and dementia participants. In Aim 2, we will predict cognitive decline in the Framework according to the newly proposed numeric staging scheme for randomized controlled trials among amyloid positive persons. In addition, since we are evaluating a representative sample of the entire community, we will also evaluate the numerical staging scheme in amyloid negative persons as well as in the entire population. Since it is recognized that cerebrovascular disease plays an important role in aging, in Aim 3 we will evaluate the impact of cerebrovascular disease in aging and cognition as well as its interactions with AD pathology. We will also develop novel MRI cerebrovascular disease measures using advanced methods. Biomarker measures of AD are often expensive and/or invasive, and, as such, are not practical from a public health perspective, and, therefore, in Aim 4, we will determine and compare the utility of plasma amyloid-beta, p-tau181, total tau and neurofilament light (NfL) as noninvasive biomarkers of cognitive decline and assess interactions with imaging biomarkers of amyloid, tau, neurodegeneration and vascular disease. Finally, since sharing the rich resources of the MCSA are important, in Aim 5, we outline our proposed mechanisms for data sharing that include review of proposals, standardized data sharing agreements and logistics for sharing the data. We are hopeful that the continuation of the MCSA will provide valuable information for the field of aging and AD.